Novo Nordisk to buy Inversago Pharma for up to $1.1B

By Bloomberg.com
| August 10, 2023

Wegovy maker Novo Nordisk A/S agreed to buy Inversago Pharma, a maker of experimental obesity and diabetes treatments, for as much as $1.08 billion.

Full story

#1

Physicians are in short supply. They are costly. Is the APP the answer to the CMO's workforce and budget challenges? ...

Amid the hype and promise, a growing tension is becoming clear: the reality of what AI can deliver versus what it can't. ...